Tests ShengXian-QuYu decoction in people with heart failure
Tests a herbal decoction against placebo in adults with heart failure.
Plain-language title generated from the registry record
Registry title: SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction
Key facts
- Where
- Baoding, Beijing, Changji, Changzhi, Chengdu, Gongyi, Jining, Korla, Linhai, Qingdao, Qinhuangdao, Tianjin, Ürümqi, Xinyuan, Yangzhou, Yining, and Zhaosu, ChinaSee the 26 sites
- Phase
- Phase 4
Where in China
- Tang County Hospital of Traditional Chinese MedicineBaoding, ChinaTaking people
- Beijing Changping Nankou HospitalBeijing, ChinaTaking people
- Beijing Fengtai Hospital of Integrated Traditional Chinese and Western MedicineBeijing, ChinaTaking people
- Changping District Traditional Chinese Medicine HospitalBeijing, ChinaTaking people
- China-Japan Friendship HospitalBeijing, ChinaTaking people
- Dongcheng District First People's HospitalBeijing, ChinaTaking people
- Dongfang Hospital Affiliated to Beijing University of Chinese MedicineBeijing, ChinaTaking people
- Huairou District Traditional Chinese Medicine Hospital of BeijingBeijing, ChinaTaking people
- Peking University People's HospitalBeijing, ChinaTaking people
- Changji Hospital of Traditional Chinese MedicineChangji, ChinaTaking people
- Changzhi Hospital of Traditional Chinese MedicineChangzhi, ChinaTaking people
- Changzhi Medical College Affiliated Heji HospitalChangzhi, ChinaTaking people
- The Affiliated Hospital of Changzhi Institute of Traditional Chinese MedicineChangzhi, ChinaTaking people
- Chengdu Integrated TCM and Western Medicine HospitalChengdu, ChinaTaking people
- Gongyi City Public Hospital of TCMGongyi, ChinaTaking people
- Jining Hospital of Traditional Chinese MedicineJining, ChinaTaking people
- Korla Hospital of Traditional Chinese MedicineKorla, ChinaTaking people
- Linhai Hospital of Traditional Chinese MedicineLinhai, ChinaTaking people
- The Affiliated Hospital of Qingdao UniversityQingdao, ChinaTaking people
- Funing Hospital of Traditional Chinese MedicineQinhuangdao, ChinaTaking people
- Jixian Chinese Traditional HospitalTianjin, ChinaTaking people
- Urumqi Hospital of Traditional Chinese MedicineÜrümqi, ChinaTaking people
- Xinyuan Traditional Chinese Medicine HospitalXinyuan, ChinaTaking people
- Yangzhou Hospital of Traditional Chinese MedicineYangzhou, ChinaTaking people
- Gulja Hospital of Traditional Chinese MedicineYining, ChinaTaking people
- Zhaosu Hospital of Traditional Chinese MedicineZhaosu, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China-Japan Friendship Hospital
- Trial code
- NCT05583773
- Record updated
- 5 November 2026
- Original description
The purpose of this study is to conduct a multicenter, randomized clinical trial to evaluate the effect of "ShengXian-QuYu Decoction" on quality of life , symptoms, and biomarkers in heart failure patients with reduced and mildly reduced ejection fraction.Read full original descriptionShow less
Effects of "ShengXian-QuYu Decoction" on Quality of Life, Symptoms, and Biomarkers in Heart Failure Patients With Reduced and Mildly Reduced Ejection Fraction: a Pragmatic, Nationwide, Multicenter, Parallel Group, Randomized, Double-Blind, Placebo-Controlled Trial
The purpose of this study is to conduct a multicenter, randomized clinical trial to evaluate the effect of "ShengXian-QuYu Decoction" on quality of life , symptoms, and biomarkers in heart failure patients with reduced and mildly reduced ejection fraction.
Inclusion: Male or female, aged ≥18 years at the time of consent; Established documented diagnosis of symptomatic HFrEF (NYHA functional class II-IV); LVEF <50%; NT-proBNP >600 pg/ml or BNP ≥150 pg/ml (or if hospitalized for heart failure within the previous 12 months, NT-proBNP ≥400 pg/ml or BNP ≥100 pg/ml) at enrolment; Provision of signed informed consent prior to any study specific procedures.
Exclusion: Current acute decompensated HF or hospitalization due to decompensated HF, ACS, stroke or transient ischemic attack (TIA), coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) or valvular repair/replacement, or other major cardiovascular surgery within 4 weeks prior to enrolment; Uncontrolled severe arrhythmia; Planned to undergo heart transplantation or device implantation; Severe infection; Active malignancy requiring treatment at the time of visit 1; Any condition outside the CV and renal disease area, such as but not limited to malignancy, with a life expectancy of less than 1 years based on investigator's clinical judgement; Heart failure due to infiltrative cardiomyopathies(cardiac amyloidosis, etc.), fulminant myocarditis, constrictive pericarditis; Inability of the patient, in the opinion of the investigator, to understand and/or comply with study medications, procedures and/or follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study; Hepatic impairment aspartate transaminase [AST] or alanine transaminase [ALT] >3x the upper limit of normal [ULN]; or total bilirubin >2x ULN at time of enrolment); eGFR <30 mL/min/1.73 m\^2 by CKD-EPI; Women of child-bearing potential who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator OR women who have a positive pregnancy test at enrolment or randomization OR women who are breast-feeding; Systolic blood pressure < 90 mmHg, or systolic blood pressure ≥ 180 mmHg, or diastolic blood pressure ≥ 110 mmHg on 2 consecutive measurements; Participation in another clinical study.